Marshfield Clinic Health System, Eau Claire, Wisconsin, USA [Current affiliation: George Washington University, Washington, DC, USA
Mayo Clinic Health System, Rochester, Minnesota, USA.
Clin Med Res. 2021 Mar;19(1):19-25. doi: 10.3121/cmr.2020.1546. Epub 2020 Oct 14.
The study objective was to determine if peri-operative bridging anticoagulation in patients with atrial fibrillation is beneficial or harmful. Systematic review and meta-analysis. Inpatient or in-hospital setting. Adults with atrial fibrillation having a CHADS2 score >1 undergoing elective surgical procedure on anticoagulation. A systemic search of multiple databases (Cochrane, Medline, PubMed) was performed regarding studies conducted on efficacy and safety of perioperative bridging anticoagulation in patients with atrial fibrillation. Studies identified were reviewed by two authors individually before inclusion. The results were then pooled using Review Manager to determine the combined effect. Stroke/systemic embolism was considered as the primary efficacy outcome. Major bleeding was the primary safety outcome. The systematic search revealed 108 potential articles. The full texts of 28 articles were retrieved for assessment of eligibility. After full text review, 25 articles were excluded. Three articles met inclusion criteria. No significant difference in stroke/systemic embolism with bridging anticoagulation was noted (risk ratio, 1.25-95% confidence interval [CI], 0.55-2.85). Bridging was associated with significantly higher risk of major bleeding (risk ratio, 3.29-95% CI, 2.25-4.81). An individualized approach is required when initiating peri-operative bridging anticoagulation. There is certainly a higher risk of bleeding with bridging anticoagulation and no difference in stroke/systemic embolism. However, the results cannot be extrapolated to patients who have valvular atrial fibrillation or CHADS2 score of 5 or greater.
研究目的在于确定在房颤患者中进行围手术期桥接抗凝治疗是否有益还是有害。系统评价和荟萃分析。住院或住院环境。正在接受抗凝治疗的 CHADS2 评分>1 的择期手术的房颤成人。对多个数据库(Cochrane、Medline、PubMed)进行了系统搜索,以查找关于房颤患者围手术期桥接抗凝治疗的疗效和安全性的研究。由两名作者独立审查确定纳入的研究。然后使用 Review Manager 汇总结果以确定综合效果。卒中/全身性栓塞被认为是主要疗效结局。大出血是主要安全性结局。系统搜索显示有 108 篇潜在文章。检索了 28 篇文章的全文以评估合格性。在全文审查后,排除了 25 篇文章。符合纳入标准的有 3 篇文章。桥接抗凝治疗与卒中/全身性栓塞无显著差异(风险比,1.25-95%置信区间 [CI],0.55-2.85)。桥接与大出血的风险显著增加相关(风险比,3.29-95% CI,2.25-4.81)。在开始围手术期桥接抗凝治疗时需要采用个体化方法。桥接抗凝治疗确实存在更高的出血风险,但在卒中/全身性栓塞方面没有差异。但是,这些结果不能外推到患有瓣膜性房颤或 CHADS2 评分≥5 的患者。